Third Wave's Q2 Clinical Dx Sales Up 24 Percent as R&D Costs Feed Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Third Wave Technologies today said second-quarter revenues grew 9 percent as R&D spending rose 73 percent and net loss widened 53 percent.  
 
Total receipts for the three months ended June 30 increased to $7.4 million from $6.8 million year over year.
 
Revenue from clinical products rose 26 percent to $6.3 million, while receipts from research products tumbled 37 percent to $1.1 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.